◎ Sugi Atlas

Atlas / Disease / Shoulder impingement syndrome

Shoulder impingement syndrome

disease
On this page

Also known as shoulder impingement syndrome (disorder) [ambiguous]

Summary

Shoulder impingement syndrome (MONDO:0006968) is a disease with 14 cohort genes (33 GWAS associations across 5 studies) and 106 clinical trials. Top therapeutic interventions include betamethasone and dexamethasone.

At a glance

  • Cohort genes: 14
  • GWAS associations: 33
  • Clinical trials: 106

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameshoulder impingement syndrome
Mondo IDMONDO:0006968
EFOEFO:1001178
MeSHD019534
DOIDDOID:14276
ICD-10-CMM75.4
SNOMED CT202849001
UMLSC0376685
MedGen138249
MedDRA10049039
Is cancer (heuristic)no

Also known as: shoulder impingement syndrome (disorder) [ambiguous]

Data availability: 33 GWAS associations (5 studies).

Disease family

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › arthropathy › shoulder impingement syndrome

Related subtypes (23): transient arthropathy, synovial plica syndrome, hypermobility syndrome, Tietze syndrome, neurogenic arthropathy, Behcet syndrome arthropathy, ankylosis, bursitis, synovium neoplasm, hydrarthrosis, articular cartilage disorder, hemarthrosis, tenosynovitis, ganglion or cyst of synovium/tendon/bursa, spondyloarthropathy, temporomandibular joint disorder, arthritic joint disease, de Quervain disease, frozen shoulder, patellofemoral pain syndrome, secondary hypertrophic osteoarthropathy, crystal arthropathy, vertebral joint disorder

Genetics & variants

GWAS landscape

33 GWAS associations across 5 studies. Top hits map to 18 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs7618045084e-10ACOT9A2.01
rs5553761441e-09LINC02303 - LINC00871T2.91
rs1443712522e-09FRMPD4A1.3
rs1456482923e-09C5orf63A1.59
rs1854966983e-09SERTM2 - EIF4BP7T3.41
rs1921101594e-09MIR3681HGG3.4
rs7755838102e-08ZNF804A - ELF2P4T3
rs5627752233e-08ASTN2 - RPL35AP22G2.1
rs9123363e-08STK24G0.86
rs1444149883e-08LINC02109G3.53
rs5339504113e-08HULCT3.59
rs131073254e-08SLC39A8T1.16
rs7509685e-08DPP3P2 - RNA5SP286G0.83
rs93029835e-07LINC01482 - ABCA8T0.83
rs38474257e-07CELF2-AS1 - USP6NLC1.3
rs71396647e-07RFC3 - VDAC1P12G0.84
rs727271372e-06RORB-AS1G1.48
rs604861742e-06GDNF-AS1T0.82
rs38071602e-06ELMO1G1.24
rs1474827204e-06ANKRD26P2T1.9
rs1171414234e-06CYP4F35P, CYP4F35PG0.53
rs7896444e-06SIPA1L2A1.17
rs177698504e-06LINC00681 - TRMT9BT0.65
rs61406375e-06PLCB1A0.79
rs1384577345e-06CPEC2.22
rs5054167e-06LINC02719 - GUCY1A2G1.28
rs21040097e-06AAR2G0.86
rs117270257e-06CCDC110 - PDLIM3G1.28
rs748215988e-06RNA5SP286 - RORB-AS1T1.57
rs1179918418e-06HSD17B6 - SDR9C7C0.77

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90080534Backman JD20216,024381,906Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084520Backman JD20216,024381,906Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST011377Kim SK20213,864614,568A Genome Wide Association Study For Shoulder Impingement and Rotator Cuff Disease.
GCST90014054Kim SK20213,864208,258A Genome Wide Association Study For Shoulder Impingement and Rotator Cuff Disease.
GCST90010423Cheng B202000Genome-Wide Association Analysis Identified ANXA1 Associated with Shoulder Impingement Syndrome in UK Biobank Samples.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding1
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic31

MAF distribution

BucketVariants
common (>=0.05)21
low_freq (0.01-0.05)1
rare (<0.01)8
unknown2

Functional consequences

ConsequenceCount
intron_variant21
intergenic_variant9
missense_variant1
non_coding_transcript_exon_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs761804508X23758874G>A0.007intergenic_variantACOT94e-10Tier 4: intronic/intergenic
rs5553761441445752452C>T0.002intergenic_variantLINC02303 - LINC008711e-09Tier 4: intronic/intergenic
rs144371252X12096802G>A0.084intron_variantFRMPD42e-09Tier 4: intronic/intergenic
rs1456482925127073401G>A0.006intron_variantC5orf633e-09Tier 4: intronic/intergenic
rs185496698X111594566C>G,T0.018intron_variantSERTM2 - EIF4BP73e-09Tier 4: intronic/intergenic
rs192110159212259621C>G,T0.001intron_variantMIR3681HG4e-09Tier 4: intronic/intergenic
rs7755838102184966287C>T0.001intergenic_variantZNF804A - ELF2P42e-08Tier 4: intronic/intergenic
rs5627752239117445618C>G0.002intron_variantASTN2 - RPL35AP223e-08Tier 4: intronic/intergenic
rs9123361398525332G>A,C0.091intron_variantSTK243e-08Tier 4: intronic/intergenic
rs144414988528949203A>G0.001intron_variantLINC021093e-08Tier 4: intronic/intergenic
rs53395041168864633C>G,T0.001intergenic_variantHULC3e-08Tier 4: intronic/intergenic
rs131073254102267552C>A,T0.074missense_variantSLC39A84e-08Tier 1: coding
rs750968973736266G>A,C0.05intron_variantDPP3P2 - RNA5SP2865e-08Tier 4: intronic/intergenic
rs93029831768790440T>G0.05intergenic_variantLINC01482 - ABCA85e-07Tier 4: intronic/intergenic
rs38474251011352895C>G0.05intron_variantCELF2-AS1 - USP6NL7e-07Tier 4: intronic/intergenic
rs71396641334053132G>A0.05intergenic_variantRFC3 - VDAC1P127e-07Tier 4: intronic/intergenic
rs72727137974251808G>A0.05intergenic_variantRORB-AS12e-06Tier 4: intronic/intergenic
rs60486174538044352T>A,G0.05intron_variantGDNF-AS12e-06Tier 4: intronic/intergenic
rs3807160736863200G>C0.05intron_variantELMO12e-06Tier 4: intronic/intergenic
rs1474827201338926751T>C0.05intron_variantANKRD26P24e-06Tier 4: intronic/intergenic
rs1171414231814323785G>A,Tintron_variantCYP4F35P, CYP4F35P4e-06Tier 4: intronic/intergenic
rs7896441232545364A>C,G0.05intron_variantSIPA1L24e-06Tier 4: intronic/intergenic
rs17769850812850478T>C0.05intron_variantLINC00681 - TRMT9B4e-06Tier 4: intronic/intergenic
rs6140637208561345A>G,T0.05intron_variantPLCB15e-06Tier 4: intronic/intergenic
rs1384577344165445578C>Tintron_variantCPE5e-06Tier 4: intronic/intergenic
rs50541611106216734G>A0.05intron_variantLINC02719 - GUCY1A27e-06Tier 4: intronic/intergenic
rs21040092036261389G>A,C,T0.05intergenic_variantAAR27e-06Tier 4: intronic/intergenic
rs117270254185496911G>A,C0.05intron_variantCCDC110 - PDLIM37e-06Tier 4: intronic/intergenic
rs74821598973973350T>A,C0.05intron_variantRNA5SP286 - RORB-AS18e-06Tier 4: intronic/intergenic
rs1179918411256869833C>A,T0.05intron_variantHSD17B6 - SDR9C78e-06Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
SLC39A8Orphanet:468699SLC39A8-CDG
FRMPD4Orphanet:777X-linked non-syndromic intellectual disability
ALG13Orphanet:324422ALG13-CDG
ALG13Orphanet:777X-linked non-syndromic intellectual disability

Cohort genes → proteins

14 cohort genes, 12 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only14

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
STK24HGNC:11403ENSG00000102572Q9Y6E0Serine/threonine-protein kinase 24gwas
UBE2D3HGNC:12476ENSG00000109332P61077Ubiquitin-conjugating enzyme E2 D3gwas
SLC38A1HGNC:13447ENSG00000111371Q9H2H9Sodium-coupled neutral amino acid symporter 1gwas
ASTN2HGNC:17021ENSG00000148219O75129Astrotactin-2gwas
ACOT9HGNC:17152ENSG00000123130Q9Y305Acyl-coenzyme A thioesterase 9, mitochondrialgwas
MIS18BP1HGNC:20190ENSG00000129534Q6P0N0Mis18-binding protein 1gwas
SLC39A8HGNC:20862ENSG00000138821Q9C0K1Metal cation symporter ZIP8gwas
ZNF804AHGNC:21711ENSG00000170396Q7Z570Zinc finger protein 804Agwas
FRMPD4HGNC:29007ENSG00000169933Q14CM0FERM and PDZ domain-containing protein 4gwas
ALG13HGNC:30881ENSG00000101901Q9NP73UDP-N-acetylglucosamine transferase subunit ALG13gwas
LSP1P3HGNC:39718ENSG00000162685LSP1 pseudogene 3gwas
C5orf63HGNC:40051ENSG00000164241A6NC05Glutaredoxin-like protein C5orf63gwas
CCAT2HGNC:47044ENSG00000280997colon cancer associated transcript 2gwas
SERTM2HGNC:48576ENSG00000260802A0A1B0GWG4Serine-rich and transmembrane domain-containing protein 2gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
STK24Serine/threonine-protein kinase 24Serine/threonine-protein kinase that acts on both serine and threonine residues and promotes apoptosis in response to stress stimuli and caspase activation.
UBE2D3Ubiquitin-conjugating enzyme E2 D3Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins.
SLC38A1Sodium-coupled neutral amino acid symporter 1Symporter that cotransports short-chain neutral amino acids and sodium ions from the extracellular to the intracellular side of the cell membrane.
ASTN2Astrotactin-2Mediates recycling of the neuronal cell adhesion molecule ASTN1 to the anterior pole of the cell membrane in migrating neurons.
ACOT9Acyl-coenzyme A thioesterase 9, mitochondrialMitochondrial acyl-CoA thioesterase.
MIS18BP1Mis18-binding protein 1Required for recruitment of CENPA to centromeres and normal chromosome segregation during mitosis.
SLC39A8Metal cation symporter ZIP8Electroneutral divalent metal cation:bicarbonate symporter of the plasma membrane mediating the cellular uptake of zinc and manganese, two divalent metal cations important for development, tissue homeostasis and immunity.
FRMPD4FERM and PDZ domain-containing protein 4Positive regulator of dendritic spine morphogenesis and density.
ALG13UDP-N-acetylglucosamine transferase subunit ALG13Catalytic subunit of the UDP-N-acetylglucosamine transferase complex that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation.
SERTM2Serine-rich and transmembrane domain-containing protein 2Promotes GDNF-mediated spinal cord motor neuron subtype specification, ensuring the maintenance of ETV4-expressing motor neurons.

Protein-family classification

Druggable: 4 · Difficult: 3 · Unknown: 7 · Druggable fraction: 0.29

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Complement119.1×0.357
Transporter15.6×0.580
Kinase12.0×0.761
Scaffold/PPI11.2×0.761
Transcription factor21.2×0.761
Other/Unknown70.9×0.761
Enzyme (other)10.9×0.761

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
STK24KinaseyesProt_kinase_dom, Kinase-like_dom_sf, Protein_kinase_ATP_BS
UBE2D3Enzyme (other)yes2.3.2.23UBC, UBQ-conjugating_enzyme/RWD, UBQ-conjugating_AS
SLC38A1Other/UnknownnoAA_transpt_TM
ASTN2ComplementyesMACPF, Astrotactin, FN3_sf
ACOT9Other/UnknownnoThioestr_dom, HotDog_dom_sf, HOTDOG_ACOT
MIS18BP1Transcription factornoSANT/Myb, Homeodomain-like_sf, SANTA
SLC39A8TransporteryesZIP, ZIP_Transporter
ZNF804ATranscription factornoZnf_C2H2_type, Znf_C2H2_sf, ZNF804A-like/GPATCH8
FRMPD4Scaffold/PPInoFERM_domain, WW_dom, PDZ
ALG13Other/UnknownnoTudor, OTU_dom, Glyco_trans_28_C
LSP1P3Other/Unknownno
C5orf63Other/UnknownnoGlutaredoxin-like, Thioredoxin-like_sf, Glutaredoxin-like_YDR286C
CCAT2Other/Unknownno
SERTM2Other/UnknownnoSERTM

Expression context

Cohort genes with no expression data: 0.

12 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)14
unknown0

Top tissues across cohort

TissueCohort genes
secondary oocyte3
buccal mucosa cell2
calcaneal tendon2
ventricular zone2
Brodmann (1909) area 232
amniotic fluid1
esophagus squamous epithelium1
oocyte1
sperm1
lateral nuclear group of thalamus1
seminal vesicle1
superficial temporal artery1
dorsal root ganglion1
trigeminal ganglion1
heart left ventricle1
monocyte1
mononuclear cell1
lower lobe of lung1
parotid gland1
visceral pleura1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
STK24295ubiquitousmarkersecondary oocyte, esophagus squamous epithelium, amniotic fluid
UBE2D3295ubiquitousmarkersecondary oocyte, oocyte, sperm
SLC38A1282ubiquitousmarkerlateral nuclear group of thalamus, seminal vesicle, superficial temporal artery
ASTN2236ubiquitousmarkerbuccal mucosa cell, trigeminal ganglion, dorsal root ganglion
ACOT9278ubiquitousmarkersecondary oocyte, heart left ventricle, calcaneal tendon
MIS18BP1239ubiquitousmarkermonocyte, mononuclear cell, ventricular zone
SLC39A8269ubiquitousmarkerparotid gland, lower lobe of lung, visceral pleura
ZNF804A144broadmarkerganglionic eminence, Brodmann (1909) area 10, Brodmann (1909) area 23
FRMPD4117broadmarkermiddle temporal gyrus, endothelial cell, Brodmann (1909) area 23
ALG13287ubiquitousmarkercalcaneal tendon, adrenal tissue, right uterine tube
LSP1P367tissue_specificyesblood, colonic epithelium, ventricular zone
C5orf63232ubiquitousmarkertendon of biceps brachii, buccal mucosa cell, left ventricle myocardium
CCAT246yesmale germ line stem cell (sensu Vertebrata) in testis, bone marrow cell, tonsil
SERTM275tissue_specificmarkerbody of uterus, myometrium, prostate gland

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
FRMPD42,222
ALG132,071
STK242,041
SLC38A11,613
ASTN21,610
ACOT91,608
SLC39A81,364
UBE2D31,200
MIS18BP11,067
ZNF804A967

Structural data

PDB: 5 · AlphaFold-only: 7 · No structure: 2

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
UBE2D3P6107745
STK24Q9Y6E040
FRMPD4Q14CM05
MIS18BP1Q6P0N04
ASTN2O751293

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
ACOT9Q9Y30585.31
SLC38A1Q9H2H979.81
SLC39A8Q9C0K173.46
SERTM2A0A1B0GWG467.49
ALG13Q9NP7354.42
ZNF804AQ7Z57045.51
C5orf63A6NC0545.45

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 48. Enrichment computed across 14 evidence-associated genes (7 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Defective ALG14 causes ALG14-CMS1815.7×0.044ALG13
Neurotransmitter uptake and metabolism In glial cells1543.8×0.044SLC38A1
Astrocytic Glutamate-Glutamine Uptake And Metabolism1271.9×0.049SLC38A1
Zinc transporters1163.1×0.049SLC39A8
Zinc influx into cells by the SLC39 gene family1163.1×0.049SLC39A8
SLC-mediated transmembrane transport216.9×0.049SLC38A1, SLC39A8
Diseases associated with N-glycosylation of proteins190.6×0.052ALG13
TICAM1, RIP1-mediated IKK complex recruitment185.9×0.052UBE2D3
Metal ion SLC transporters185.9×0.052SLC39A8
IKK complex recruitment mediated by RIP1170.9×0.052UBE2D3
Apoptotic cleavage of cellular proteins168.0×0.052STK24
Apoptotic execution phase168.0×0.052STK24
Nucleosome assembly168.0×0.052MIS18BP1
Inactivation of CSF3 (G-CSF) signaling162.8×0.052UBE2D3
Mitochondrial Fatty Acid Beta-Oxidation154.4×0.052ACOT9
Downregulation of SMAD2/3:SMAD4 transcriptional activity152.6×0.052UBE2D3
Signaling by BMP151.0×0.052UBE2D3
PINK1-PRKN Mediated Mitophagy151.0×0.052UBE2D3
Negative regulators of DDX58/IFIH1 signaling146.6×0.053UBE2D3
Cyclin A/B1/B2 associated events during G2/M transition144.1×0.053MIS18BP1
Amino acid transport across the plasma membrane142.9×0.053SLC38A1
Transport of small molecules27.2×0.063SLC38A1, SLC39A8
Regulation of TNFR1 signaling132.0×0.063UBE2D3
Chromosome Maintenance130.2×0.063MIS18BP1
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein129.7×0.063ALG13
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha128.1×0.063UBE2D3
E3 ubiquitin ligases ubiquitinate target proteins127.6×0.063UBE2D3
R-HSA-425366125.9×0.065SLC39A8
Peroxisomal protein import124.7×0.066UBE2D3
Apoptosis124.0×0.066STK24

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 10 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
leukocyte adhesion to arterial endothelial cell11685.2×0.013SLC39A8
plasma membrane selenite transport11685.2×0.013SLC39A8
mitochondrial manganese ion transmembrane transport11685.2×0.013SLC39A8
protein N-linked glycosylation252.7×0.013SLC39A8, ALG13
mercury ion transport1842.6×0.013SLC39A8
iron ion import across plasma membrane1842.6×0.013SLC39A8
short-chain fatty acid metabolic process1561.7×0.013ACOT9
positive regulation of synapse structural plasticity1561.7×0.013FRMPD4
manganese ion transmembrane transport1561.7×0.013SLC39A8
cellular detoxification of cadmium ion1561.7×0.013SLC39A8
obsolete pericentric heterochromatin organization1561.7×0.013MIS18BP1
intracellular manganese ion homeostasis1337.0×0.014SLC39A8
amino acid import1337.0×0.014SLC38A1
establishment of body hair planar orientation1337.0×0.014ASTN2
cadmium ion transmembrane transport1337.0×0.014SLC39A8
positive regulation of dendritic spine maintenance1337.0×0.014ZNF804A
cartilage homeostasis1337.0×0.014SLC39A8
L-alpha-amino acid transmembrane transport1280.9×0.016SLC38A1
arginine metabolic process1240.7×0.016SLC39A8
cobalt ion transport1240.7×0.016SLC39A8
regulation of axon regeneration1240.7×0.016STK24
GABA biosynthetic process1210.7×0.017SLC38A1
L-glutamine import across plasma membrane1210.7×0.017SLC38A1
zinc ion import across plasma membrane1168.5×0.020SLC39A8
zinc ion transport1153.2×0.021SLC39A8
CENP-A containing chromatin assembly1153.2×0.021MIS18BP1
neurotransmitter uptake1140.4×0.021SLC38A1
L-glutamine transport1140.4×0.021SLC38A1
negative regulation of protein localization to cell surface1129.6×0.022ASTN2
intracellular monoatomic cation homeostasis1112.3×0.024SLC39A8

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
Tranexamic AcidPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Lidocaine, Methylprednisolone Acetate, Sodium Chloride, Tetracaine.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 13

Druggability breadth: 4 of 14 evidence-associated genes (29%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
STK24NERATINIB

Top cohort targets by molecule count

SymbolMoleculesMax phase
STK24184
UBE2D300
SLC38A100
ASTN200
ACOT900
MIS18BP100
SLC39A800
ZNF804A00
FRMPD400
ALG1300

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
NERATINIB4STK24
BOSUTINIB4STK24
GILTERITINIB4STK24
NINTEDANIB4STK24
SUNITINIB4STK24
QUIZARTINIB4STK24
LOSMAPIMOD3STK24
CRENOLANIB3STK24
DOVITINIB3STK24
LESTAURTINIB3STK24
SU-0148132STK24
GOLVATINIB2STK24
TOZASERTIB2STK24
PELITINIB2STK24
KW-24491STK24
PF-037583091STK24
PF-038147351STK24
AST-4871STK24

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
STK24314Binding:314
UBE2D318Binding:18
SLC38A12Binding:2
ACOT91Binding:1

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
UBE2D32.3.2.23, 2.3.2.24E2 ubiquitin-conjugating enzyme, (E3-independent) E2 ubiquitin-conjugating enzyme

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
STK24314

Pharmacogenomics

Cohort genes with a PharmGKB record: 12; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

18 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
NERATINIB4STK24
BOSUTINIB4STK24
GILTERITINIB4STK24
NINTEDANIB4STK24
SUNITINIB4STK24
QUIZARTINIB4STK24
LOSMAPIMOD3STK24
CRENOLANIB3STK24
DOVITINIB3STK24
LESTAURTINIB3STK24
SU-0148132STK24
GOLVATINIB2STK24
TOZASERTIB2STK24
PELITINIB2STK24
KW-24491STK24
PF-037583091STK24
PF-038147351STK24
AST-4871STK24

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)1STK24
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug2UBE2D3, ASTN2
DDruggable family + AlphaFold only, no drug1SLC39A8
EDifficult family or no structure, no drug10SLC38A1, ACOT9, MIS18BP1, ZNF804A, FRMPD4, ALG13, LSP1P3, C5orf63, CCAT2, SERTM2

Undrugged target profiles

13 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
UBE2D318—
SLC38A12—
ASTN20—
ACOT91—
MIS18BP10—
SLC39A80—
ZNF804A0—
FRMPD40—
ALG130—
LSP1P30—
C5orf630—
CCAT20—
SERTM20—

Clinical trials & evidence

Clinical trials

Clinical trials: 106.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified100
PHASE32
PHASE22
PHASE41
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01414569PHASE4COMPLETEDDexamethasone for Pain After Shoulder Surgery
NCT00196573PHASE3UNKNOWNSubacromial Decompression Versus Subacromial Bursectomy for Patients With Rotator Cuff Tendinosis
NCT01441830PHASE3UNKNOWNRadial Extracorporeal Shock Wave Therapy (rESWT) Treatment of Subacromial Shoulder Pain
NCT00632996PHASE2COMPLETEDExercise and Manual Therapy for Shoulder Subacromial Impingement Syndrome
NCT01055444PHASE2COMPLETEDStudy Evaluating Heated Lidocaine/Tetracaine Topical Patch in Treatment of Patients With Shoulder Impingement Syndrome
NCT03167138EARLY_PHASE1UNKNOWNMicro-Fragmented Adipose Tissue (Lipogems®) Injection for Chronic Shoulder Pain in Persons With Spinal Cord Injury
NCT05957952Not specifiedACTIVE_NOT_RECRUITINGThe Effects of Dynamic Taping With Exercise on Neuromuscular Control in Individuals With Subacromial Impingement
NCT06092502Not specifiedRECRUITINGShoulder Impingement Syndrome and Graded Motor Imagery
NCT06195956Not specifiedRECRUITINGThe Effect of Lower Limb Kinetic Chain Exercise in Shoulder Impingement
NCT06407804Not specifiedRECRUITINGEffects of Thrower’s Ten and Routine Physical Therapy in Patients With Shoulder Impingement Syndrome
NCT06435494Not specifiedENROLLING_BY_INVITATIONCross-sectorial Use of Patient-Reported Outcomes in Chronic Degenerative Shoulder Conditions
NCT06457542Not specifiedACTIVE_NOT_RECRUITINGComparative Effects of ART and STM in Shoulder Impingement Syndrome
NCT06713005Not specifiedNOT_YET_RECRUITINGThe Clinical Efficacy of Different Durations of Suprascapular Nerve Pulsed Radiofrequency
NCT06732570Not specifiedACTIVE_NOT_RECRUITINGEffect of High Intensity Laser on Shoulder Impingement.
NCT06754592Not specifiedNOT_YET_RECRUITINGRole of Dynamic Ultrasound in Assessment of Shoulder Impingement Syndrome
NCT06759935Not specifiedRECRUITINGPerformance and Safety of LightForce® Therapy Lasers on Shoulder Soft Tissue Inflammation Pain Reduction
NCT06789991Not specifiedNOT_YET_RECRUITINGElectromyographic Activity of Posterior Oblique Sling Muscles in Patients With Shoulder Impingement Syndrome
NCT07190768Not specifiedNOT_YET_RECRUITINGEffectiveness of Kinesiologic Taping and Dry Needling in the Treatment of Subacromial Pain Syndrome
NCT07228936Not specifiedRECRUITINGThe Role of Pectoralis Minor Tightness in the Development of Rotator Cuff Tears
NCT07237789Not specifiedNOT_YET_RECRUITINGImpact of Core Stability Training on Function in Patient With Shoulder Impingement Syndrome Among Manual Operated Hand Workers
NCT07290660Not specifiedRECRUITINGGraded Motor Imagery and Task-Oriented Exercise in Shoulder Impingement
NCT07521839Not specifiedACTIVE_NOT_RECRUITINGTitle of This Study is to Evaluate the Effects of Abdominal Drawing in Maneuver With Cross Pattern Limb Exercises in Patients With Subacromial Impingement Syndrome
NCT07577791Not specifiedNOT_YET_RECRUITINGProne Row Exercise Versus Lateral Pull Down Exercise In Shoulder Impingement Syndrome With Scapular Dyskinesia
NCT00290888Not specifiedCOMPLETEDArthroscopic Rotator Cuff Repair of Full Thickness Tears With and Without Arthroscopic Acromioplasty
NCT00349648Not specifiedUNKNOWNConservative or Operative Treatment for the Shoulder Impingement Syndrome?
NCT00633451Not specifiedCOMPLETEDRandomized Clinical Trial of Rehabilitation for Subacromial Impingement Syndrome
NCT01073956Not specifiedUNKNOWNEfficacy of Electrotherapy in Subacromial Impingement Syndrome
NCT01090271Not specifiedCOMPLETEDEffects of Eccentric Training for Shoulder Abductors in Subjects With Shoulder Impingement Syndrome
NCT01190891Not specifiedCOMPLETEDPhysical Therapy Versus Steroid Injection for Shoulder Impingement Syndrome
NCT01257113Not specifiedCOMPLETEDSupervised Exercise Therapy vs Home Exercises for Patients With Subacromial Impingement
NCT01314196Not specifiedCOMPLETEDProgressive Resistance Training of the Biceps in Subacromial Impingement Syndrome
NCT01465932Not specifiedCOMPLETEDEffectiveness of Physical Therapy Program to Treat Rotator Cuff Disorders Among Nursing Professionals
NCT01508715Not specifiedCOMPLETEDComparison of Exercise Interventions in Adults With Subacromial Impingement Syndrome
NCT01623011Not specifiedCOMPLETEDCan Shoulder Arthroscopy Work
NCT01785745Not specifiedCOMPLETEDStudy of Neurocognitive Therapeutic Exercise in the Shoulder Impingement Syndrome in Comparison With Traditional Therapeutic Exercise
NCT01885377Not specifiedCOMPLETEDSWESS: The SWedish Exercise Shoulder Study in Primary Care for Patients With Subacromial Pain
NCT02019537Not specifiedCOMPLETEDSubacromial Injection of Allogeneic Platelet Rich Plasma (PRP) for Shoulder Impingement Syndrome
NCT02043639Not specifiedTERMINATEDClinicCompanion. Compared to the Use of a Goniometer
NCT02083796Not specifiedCOMPLETEDShort-term Effects of Thoracic Manipulation in Shoulder Impingement
NCT02172079Not specifiedCOMPLETEDMobilization With Movement for Shoulder Impingement

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
BETAMETHASONE41
DEXAMETHASONE41

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 71

This page pulls from 71 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncicd10cmintactinterpromeddramedgenmeshmimmondomondochildmondoparentorphanetpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot